Cemiplimab for treating advanced cutaneous squamous cell carcinoma

2.1 Cemiplimab (Libtayo, Sanofi) 'as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation'.

2.2 The dosage schedule is available in the summary of product characteristics for cemiplimab.

2.3 The list price for cemiplimab is £4,650 per 350 mg vial (excluding VAT; BNF online accessed April 2022). The cost per course of treatment is £4,650. The cost for 1 year of treatment with cemiplimab based on the list price is £80,877.

2.4 The company has a commercial arrangement. This makes cemiplimab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.